The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches
Abstract
:Simple Summary
Abstract
1. Introduction
1.1. Writers
1.2. Erasers
1.3. Readers
2. m6A Regulation in Glioblastoma
2.1. Writers
2.2. Erasers
2.3. Readers
3. Therapeutic Targets
3.1. FTO Inhibitors
3.2. METTL3 Inhibitors
3.3. Inducible Editing of m6A Modifications via CRISPR-Cas Strategies
4. R-Loops
5. Future Directions
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Boulias, K.; Greer, E.L. Biological roles of adenine methylation in RNA. Nat. Rev. Genet. 2022, 24, 143–160. [Google Scholar] [CrossRef] [PubMed]
- Dominissini, D.; Moshitch-Moshkovitz, S.; Schwartz, S.; Salmon-Divon, M.; Ungar, L.; Osenberg, S.; Cesarkas, K.; Jacob-Hirsch, J.; Amariglio, N.; Kupiec, M.; et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 2012, 485, 201–206. [Google Scholar] [CrossRef] [PubMed]
- Meyer, K.D.; Saletore, Y.; Zumbo, P.; Elemento, O.; Mason, C.E.; Jaffrey, S.R. Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons. Cell 2012, 149, 1635–1646. [Google Scholar] [CrossRef] [Green Version]
- Tegowski, M.; Flamand, M.N.; Meyer, K.D. scDART-seq reveals distinct m6A signatures and mRNA methylation heterogeneity in single cells. Mol. Cell 2022, 82, 868–878.e10. [Google Scholar] [CrossRef]
- Shi, H.; Wei, J.; He, C. Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol. Cell 2019, 74, 640–650. [Google Scholar] [CrossRef]
- Lence, T.; Paolantoni, C.; Worpenberg, L.; Roignant, J.-Y. Mechanistic insights into m6A RNA enzymes. Biochim. Biophys. Acta (BBA)—Gene Regul. Mech. 2019, 1862, 222–229. [Google Scholar] [CrossRef]
- Liu, J.; Yue, Y.; Han, D.; Wang, X.; Fu, Y.; Zhang, L.; Jia, G.; Yu, M.; Lu, Z.; Deng, X.; et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 2014, 10, 93–95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murakami, S.; Jaffrey, S.R. Hidden codes in mRNA: Control of gene expression by m6A. Mol. Cell 2022, 82, 2236–2251. [Google Scholar] [CrossRef]
- Liu, J.; Yue, Y.; Liu, J.; Cui, X.; Cao, J.; Luo, G.; Zhang, Z.; Cheng, T.; Gao, M.; Shu, X.; et al. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018, 4, 10. [Google Scholar] [CrossRef] [Green Version]
- Wen, J.; Lv, R.; Ma, H.; Shen, H.; He, C.; Wang, J.; Jiao, F.; Liu, H.; Yang, P.; Tan, L.; et al. Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Mol. Cell 2018, 69, 1028–1038.e6. [Google Scholar] [CrossRef] [Green Version]
- Ping, X.-L.; Sun, B.-F.; Wang, L.; Xiao, W.; Yang, X.; Wang, W.-J.; Adhikari, S.; Shi, Y.; Lv, Y.; Chen, Y.-S.; et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014, 24, 177–189. [Google Scholar] [CrossRef] [Green Version]
- Jia, G.; Fu, Y.; Zhao, X.; Dai, Q.; Zheng, G.; Yang, Y.; Yi, C.; Lindahl, T.; Pan, T.; Yang, Y.-G.; et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 2011, 7, 885–887. [Google Scholar] [CrossRef]
- Zheng, G.; Dahl, J.A.; Niu, Y.; Fedorcsak, P.; Huang, C.-M.; Li, C.J.; Vågbø, C.B.; Shi, Y.; Wang, W.-L.; Song, S.-H.; et al. ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility. Mol. Cell 2013, 49, 18–29. [Google Scholar] [CrossRef] [Green Version]
- Wei, J.; Liu, F.; Lu, Z.; Fei, Q.; Ai, Y.; He, P.C.; Shi, H.; Cui, X.; Su, R.; Klungland, A.; et al. Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol. Cell 2018, 71, 973–985.e5. [Google Scholar] [CrossRef] [Green Version]
- Hess, M.E.; Hess, S.; Meyer, K.D.; Verhagen, L.A.W.; Koch, L.; Brönneke, H.S.; Dietrich, M.O.; Jordan, S.D.; Saletore, Y.; Elemento, O.; et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat. Neurosci. 2013, 16, 1042–1048. [Google Scholar] [CrossRef]
- Mauer, J.; Jaffrey, S.R. FTO, m6Am, and the hypothesis of reversible epitranscriptomic mRNA modifications. FEBS Lett. 2018, 592, 2012–2022. [Google Scholar] [CrossRef] [Green Version]
- McIntyre, A.B.R.; Gokhale, N.S.; Cerchietti, L.; Jaffrey, S.R.; Horner, S.M.; Mason, C.E. Limits in the detection of m6A changes using MeRIP/m6A-seq. Sci. Rep. 2020, 10, 6590. [Google Scholar] [CrossRef] [Green Version]
- Rosa-Mercado, N.A.; Withers, J.B.; Steitz, J.A. Settling the m6A debate: Methylation of mature mRNA is not dynamic but accelerates turnover. Genes Dev. 2017, 31, 957–958. [Google Scholar] [CrossRef] [Green Version]
- Xu, Y.; Zhang, W.; Shen, F.; Yang, X.; Liu, H.; Dai, S.; Sun, X.; Huang, J.; Guo, Q. YTH Domain Proteins: A Family of m6A Readers in Cancer Progression. Front. Oncol. 2021, 11, 629560. [Google Scholar] [CrossRef]
- Liao, S.; Sun, H.; Xu, C. YTH Domain: A Family of N 6-methyladenosine (m6A) Readers. Genom. Proteom. Bioinform. 2018, 16, 99–107. [Google Scholar] [CrossRef]
- Hao, W.; Dian, M.; Zhou, Y.; Zhong, Q.; Pang, W.; Li, Z.; Zhao, Y.; Ma, J.; Lin, X.; Luo, R.; et al. Autophagy induction promoted by m6A reader YTHDF3 through translation upregulation of FOXO3 mRNA. Nat. Commun. 2022, 13, 5845. [Google Scholar] [CrossRef]
- Wang, X.; Zhao, B.S.; Roundtree, I.A.; Lu, Z.; Han, D.; Ma, H.; Weng, X.; Chen, K.; Shi, H.; He, C. N6-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell 2015, 161, 1388–1399. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Lu, Z.; Gomez, A.; Hon, G.C.; Yue, Y.; Han, D.; Fu, Y.; Parisien, M.; Dai, Q.; Jia, G.; et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 2014, 505, 117–120. [Google Scholar] [CrossRef] [Green Version]
- Du, H.; Zhao, Y.; He, J.; Zhang, Y.; Xi, H.; Liu, M.; Ma, J.; Wu, L. YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4–NOT deadenylase complex. Nat. Commun. 2016, 7, 12626. [Google Scholar] [CrossRef]
- Patil, D.P.; Pickering, B.F.; Jaffrey, S.R. Reading m6A in the Transcriptome: m6A-Binding Proteins. Trends Cell Biol. 2018, 28, 113–127. [Google Scholar] [CrossRef]
- Zaccara, S.; Jaffrey, S.R. A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNA. Cell 2020, 181, 1582–1595.e18. [Google Scholar] [CrossRef]
- Ries, R.J.; Zaccara, S.; Klein, P.; Olarerin-George, A.; Namkoong, S.; Pickering, B.F.; Patil, D.P.; Kwak, H.; Lee, J.H.; Jaffrey, S.R. m6A enhances the phase separation potential of mRNA. Nature 2019, 571, 424–428. [Google Scholar] [CrossRef]
- Yan, H.; Zhang, L.; Cui, X.; Zheng, S.; Li, R. Roles and mechanisms of the m6A reader YTHDC1 in biological processes and diseases. Cell Death Discov. 2022, 8, 237. [Google Scholar] [CrossRef]
- Zaccara, S.; Ries, R.J.; Jaffrey, S.R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. 2019, 20, 608–624. [Google Scholar] [CrossRef]
- Alarcón, C.R.; Goodarzi, H.; Lee, H.; Liu, X.; Tavazoie, S.; Tavazoie, S.F. HNRNPA2B1 Is a Mediator of m6A-Dependent Nuclear RNA Processing Events. Cell 2015, 162, 1299–1308. [Google Scholar] [CrossRef] [Green Version]
- Liu, N.; Dai, Q.; Zheng, G.; He, C.; Parisien, M.; Pan, T. N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions. Nature 2015, 518, 560–564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, H.; Weng, H.; Sun, W.; Qin, X.; Shi, H.; Wu, H.; Zhao, B.S.; Mesquita, A.; Liu, C.; Yuan, C.L.; et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 2018, 20, 285–295. [Google Scholar] [CrossRef]
- Sun, L.; Fazal, F.M.; Li, P.; Broughton, J.P.; Lee, B.; Tang, L.; Huang, W.; Kool, E.T.; Chang, H.Y.; Zhang, Q.C. RNA structure maps across mammalian cellular compartments. Nat. Struct. Mol. Biol. 2019, 26, 322–330. [Google Scholar] [CrossRef] [PubMed]
- Yoon, K.-J.; Ringeling, F.R.; Vissers, C.; Jacob, F.; Pokrass, M.; Jimenez-Cyrus, D.; Su, Y.; Kim, N.-S.; Zhu, Y.; Zheng, L.; et al. Temporal Control of Mammalian Cortical Neurogenesis by m6A Methylation. Cell 2017, 171, 877–889.e17. [Google Scholar] [CrossRef] [Green Version]
- Livneh, I.; Moshitch-Moshkovitz, S.; Amariglio, N.; Rechavi, G.; Dominissini, D. The m6A epitranscriptome: Transcriptome plasticity in brain development and function. Nat. Rev. Neurosci. 2020, 21, 36–51. [Google Scholar] [CrossRef]
- Li, L.; Zang, L.; Zhang, F.; Chen, J.; Shen, H.; Shu, L.; Liang, F.; Feng, C.; Chen, D.; Tao, H.; et al. Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Hum. Mol. Genet. 2017, 26, 2398–2411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, M.; Zhao, X.; Wang, W.; Shi, H.; Pan, Q.; Lu, Z.; Perez, S.P.; Suganthan, R.; He, C.; Bjørås, M.; et al. Ythdf2-mediated m6A mRNA clearance modulates neural development in mice. Genome Biol. 2018, 19, 69. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Li, Y.; Yue, M.; Wang, J.; Kumar, S.; Wechsler-Reya, R.J.; Zhang, Z.; Ogawa, Y.; Kellis, M.; Duester, G.; et al. N6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications. Nat. Neurosci. 2018, 21, 195–206. [Google Scholar] [CrossRef] [Green Version]
- Barbieri, I.; Kouzarides, T. Role of RNA modifications in cancer. Nat. Rev. Cancer 2020, 20, 303–322. [Google Scholar] [CrossRef]
- Huang, H.; Weng, H.; Deng, X.; Chen, J. RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications. Annu. Rev. Cancer Biol. 2020, 4, 221–240. [Google Scholar] [CrossRef] [Green Version]
- Gimple, R.C.; Yang, K.; Halbert, M.E.; Agnihotri, S.; Rich, J.N. Brain cancer stem cells: Resilience through adaptive plasticity and hierarchical heterogeneity. Nat. Rev. Cancer 2022, 22, 497–514. [Google Scholar] [CrossRef] [PubMed]
- Couturier, C.P.; Ayyadhury, S.; Le, P.U.; Nadaf, J.; Monlong, J.; Riva, G.; Allache, R.; Baig, S.; Yan, X.; Bourgey, M.; et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 2020, 11, 3406. [Google Scholar] [CrossRef] [PubMed]
- Fabbri, L.; Chakraborty, A.; Robert, C.; Vagner, S. The plasticity of mRNA translation during cancer progression and therapy resistance. Nat. Rev. Cancer 2021, 21, 558–577. [Google Scholar] [CrossRef]
- Li, P.; Richard, H.T.; Zhu, K.; Li, L.; Huang, S. The Roles and Regulation of m6A Modification in Glioblastoma Stem Cells and Tumorigenesis. Biomedicines 2022, 10, 969. [Google Scholar] [CrossRef]
- Xu, Z.; Jiang, J.; Wang, S. The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer. Cell. Mol. Neurobiol. 2022. Online ahead of print. [Google Scholar] [CrossRef]
- Qu, S.; Chen, Z.; Liu, B.; Liu, J.; Wang, H. N6-methyladenine-related genes affect biological behavior and the prognosis of glioma. Cancer Med. 2021, 10, 98–108. [Google Scholar] [CrossRef]
- Xie, P.; Yan, H.; Gao, Y.; Li, X.; Zhou, D.-B.; Liu, Z.-Q. Construction of m6A-Related lncRNA Prognostic Signature Model and Immunomodulatory Effect in Glioblastoma Multiforme. Front. Oncol. 2022, 12, 920926. [Google Scholar] [CrossRef]
- Chai, R.-C.; Wu, F.; Wang, Q.-X.; Zhang, S.; Zhang, K.-N.; Liu, Y.-Q.; Zhao, Z.; Jiang, T.; Wang, Y.-Z.; Kang, C.-S. m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging 2019, 11, 1204–1225. [Google Scholar] [CrossRef]
- Visvanathan, A.; Patil, V.; Arora, A.; Hegde, A.S.; Arivazhagan, A.; Santosh, V.; Somasundaram, K. Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance. Oncogene 2018, 37, 522–533. [Google Scholar] [CrossRef]
- Chang, Y.-Z.; Chai, R.-C.; Pang, B.; Chang, X.; An, S.Y.; Zhang, K.-N.; Jiang, T.; Wang, Y.-Z. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma. Cancer Lett. 2021, 511, 36–46. [Google Scholar] [CrossRef]
- Visvanathan, A.; Patil, V.; Abdulla, S.; Hoheisel, J.D.; Somasundaram, K. N6-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes 2019, 10, 141. [Google Scholar] [CrossRef] [Green Version]
- Shi, J.; Chen, G.; Dong, X.; Li, H.; Li, S.; Cheng, S.; Li, Y.; Wang, L.; Yuan, J.; Qian, Z.; et al. METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner. Front. Oncol. 2021, 11, 702983. [Google Scholar] [CrossRef]
- Li, F.; Yi, Y.; Miao, Y.; Long, W.; Long, T.; Chen, S.; Cheng, W.; Zou, C.; Zheng, Y.; Wu, X.; et al. N6-Methyladenosine Modulates Nonsense-Mediated mRNA Decay in Human Glioblastoma. Cancer Res. 2019, 79, 5785–5798. [Google Scholar] [CrossRef] [Green Version]
- Tassinari, V.; Cesarini, V.; Tomaselli, S.; Ianniello, Z.; Silvestris, D.A.; Ginistrelli, L.C.; Martini, M.; De Angelis, B.; De Luca, G.; Vitiani, L.R.; et al. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021, 22, 51. [Google Scholar] [CrossRef] [PubMed]
- Suvà, M.L.; Rheinbay, E.; Gillespie, S.M.; Patel, A.P.; Wakimoto, H.; Rabkin, S.D.; Riggi, N.; Chi, A.S.; Cahill, D.P.; Nahed, B.V.; et al. Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells. Cell 2014, 157, 580–594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Filippova, N.; Yang, X.; Wang, Y.; Gillespie, G.Y.; Langford, C.; King, P.H.; Wheeler, C.; Nabors, L.B. The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance. Mol. Cancer Res. 2011, 9, 648–659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, F.; Chen, S.; Yu, J.; Gao, Z.; Sun, Z.; Yi, Y.; Long, T.; Zhang, C.; Li, Y.; Pan, Y.; et al. Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma. Clin. Transl. Med. 2021, 11, e553. [Google Scholar] [CrossRef]
- Cui, Q.; Shi, H.; Ye, P.; Li, L.; Qu, Q.; Sun, G.; Sun, G.; Lu, Z.; Huang, Y.; Yang, C.-G.; et al. m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell Rep. 2017, 18, 2622–2634. [Google Scholar] [CrossRef]
- Tao, M.; Li, X.; He, L.; Rong, X.; Wang, H.; Pan, J.; Lu, Z.; Zhang, X.; Peng, Y. Decreased RNA m6A Methylation Enhances the Process of the Epithelial Mesenchymal Transition and Vasculogenic Mimicry in Glioblastoma. Am. J. Cancer Res. 2022, 12, 893–906. [Google Scholar]
- Zhang, S.; Zhao, B.S.; Zhou, A.; Lin, K.; Zheng, S.; Lu, Z.; Chen, Y.; Sulman, E.P.; Xie, K.; Bögler, O.; et al. m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell 2017, 31, 591–606.e6. [Google Scholar] [CrossRef] [Green Version]
- Zhang, N.; Wei, P.; Gong, A.; Chiu, W.-T.; Lee, H.-T.; Colman, H.; Huang, H.; Xue, J.; Liu, M.; Wang, Y.; et al. FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis. Cancer Cell 2011, 20, 427–442. [Google Scholar] [CrossRef] [Green Version]
- Liu, M.; Dai, B.; Kang, S.-H.; Ban, K.; Huang, F.-J.; Lang, F.F.; Aldape, K.D.; Xie, T.-X.; Pelloski, C.E.; Xie, K.; et al. FoxM1B Is Overexpressed in Human Glioblastomas and Critically Regulates the Tumorigenicity of Glioma Cells. Cancer Res. 2006, 66, 3593–3602. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dong, F.; Qin, X.; Wang, B.; Li, Q.; Hu, J.; Cheng, X.; Guo, D.; Cheng, F.; Fang, C.; Tan, Y.; et al. ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment. Cancer Res. 2021, 81, 5876–5888. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Samanta, D.; Lu, H.; Bullen, J.W.; Zhang, H.; Chen, I.; He, X.; Semenza, G.L. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc. Natl. Acad. Sci. USA 2016, 113, E2047–E2056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kowalski-Chauvel, A.; Lacore, M.G.; Arnauduc, F.; Delmas, C.; Toulas, C.; Cohen-Jonathan-Moyal, E.; Seva, C. The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells. Cancers 2021, 13, 40. [Google Scholar] [CrossRef]
- Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.-H.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.-M.; Gallia, G.L.; et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 2008, 321, 1807–1812. [Google Scholar] [CrossRef] [Green Version]
- Elkashef, S.M.; Lin, A.-P.; Myers, J.; Sill, H.; Jiang, D.; Dahia, P.L.; Aguiar, R.C. IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation. Cancer Cell 2017, 31, 619–620. [Google Scholar] [CrossRef] [Green Version]
- Su, R.; Dong, L.; Li, C.; Nachtergaele, S.; Wunderlich, M.; Qing, Y.; Deng, X.; Wang, Y.; Weng, X.; Hu, C.; et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell 2018, 172, 90–105.e23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Z.; Weng, H.; Su, R.; Weng, X.; Zuo, Z.; Li, C.; Huang, H.; Nachtergaele, S.; Dong, L.; Hu, C.; et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell 2017, 31, 127–141. [Google Scholar] [CrossRef] [Green Version]
- Lv, D.; Ding, S.; Zhong, L.; Tu, J.; Li, H.; Yao, H.; Zou, Y.; Zeng, Z.; Liao, Y.; Wan, X.; et al. M6A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression. Oncogene 2022, 41, 1727–1741. [Google Scholar] [CrossRef]
- Xiao, L.; Li, X.; Mu, Z.; Zhou, J.; Zhou, P.; Xie, C.; Jiang, S. FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma. Cancer Res. 2020, 80, 3945–3958. [Google Scholar] [CrossRef]
- Xu, C.; Yuan, B.; He, T.; Ding, B.; Li, S. Prognostic values of YTHDF1 regulated negatively by mir-3436 in Glioma. J. Cell. Mol. Med. 2020, 24, 7538–7549. [Google Scholar] [CrossRef] [PubMed]
- Yarmishyn, A.A.; Yang, Y.-P.; Lu, K.-H.; Chen, Y.-C.; Chien, Y.; Chou, S.-J.; Tsai, P.-H.; Ma, H.-I.; Chien, C.-S.; Chen, M.-T.; et al. Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1. Cancer Cell Int. 2020, 20, 597. [Google Scholar] [CrossRef] [PubMed]
- Fang, R.; Chen, X.; Zhang, S.; Shi, H.; Ye, Y.; Shi, H.; Zou, Z.; Li, P.; Guo, Q.; Ma, L.; et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat. Commun. 2021, 12, 177. [Google Scholar] [CrossRef]
- Chai, R.-C.; Chang, Y.-Z.; Chang, X.; Pang, B.; An, S.Y.; Zhang, K.-N.; Chang, Y.-H.; Jiang, T.; Wang, Y.-Z. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma. J. Hematol. Oncol. 2021, 14, 109. [Google Scholar] [CrossRef]
- Chen, Y.; Wang, Y.; Qiu, K.; Cao, Y.; Zhang, F.; Zhao, H.; Liu, X. YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF-κB signalling pathways via inhibiting EPHB3 and TNFAIP3. Clin. Transl. Immunol. 2022, 11, e1393. [Google Scholar] [CrossRef]
- Dixit, D.; Prager, B.C.; Gimple, R.C.; Poh, H.X.; Wang, Y.; Wu, Q.; Qiu, Z.; Kidwell, R.L.; Kim, L.J.Y.; Xie, Q.; et al. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021, 11, 480–499. [Google Scholar] [CrossRef]
- Chang, G.; Shi, L.; Ye, Y.; Shi, H.; Zeng, L.; Tiwary, S.; Huse, J.T.; Huo, L.; Ma, L.; Ma, Y.; et al. YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell 2020, 38, 857–871.e7. [Google Scholar] [CrossRef] [PubMed]
- Han, D.; Liu, J.; Chen, C.; Dong, L.; Liu, Y.; Chang, R.; Huang, X.; Liu, Y.; Wang, J.; Dougherty, U.; et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 2019, 566, 270–274. [Google Scholar] [CrossRef] [PubMed]
- Lin, X.; Wang, Z.; Yang, G.; Wen, G.; Zhang, H. YTHDF2 Correlates with Tumor Immune Infiltrates in Lower-Grade Glioma. Aging 2020, 12, 18476–18500. [Google Scholar] [CrossRef]
- Zhu, X.; Yang, H.; Zhang, M.; Wu, X.; Jiang, L.; Liu, X.; Lv, K. YTHDC1-mediated VPS25 regulates cell cycle by targeting JAK-STAT signaling in human glioma cells. Cancer Cell Int. 2021, 21, 645. [Google Scholar] [CrossRef]
- Cun, Y.; An, S.; Zheng, H.; Lan, J.; Chen, W.; Luo, W.; Yao, C.; Li, X.; Huang, X.; Sun, X.; et al. Specific Regulation of m6A by SRSF7 Promotes the Progression of Glioblastoma. Genom. Proteom. Bioinform. 2022. Online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.-C.; Chen, S.-H.; Shen, X.-L.; Li, D.-C.; Liu, H.-Y.; Ji, Y.-L.; Li, M.; Yu, K.; Yang, H.; Chen, J.-J.; et al. M6A RNA Methylation Regulator HNRNPC Contributes to Tumorigenesis and Presdicts Prognosis in Glioblastoma Multiforme. Front. Oncol. 2020, 10, 536875. [Google Scholar] [CrossRef] [PubMed]
- Deng, J.; Chen, S.; Wang, F.; Zhao, H.; Xie, Z.; Xu, Z.; Zhang, Q.; Liang, P.; Zhai, X.; Cheng, Y. Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival. Mol. Neurobiol. 2016, 53, 1132–1144. [Google Scholar] [CrossRef]
- Park, Y.M.; Hwang, S.J.; Masuda, K.; Choi, K.-M.; Jeong, M.-R.; Nam, D.-H.; Gorospe, M.; Kim, H.H. Heterogeneous Nuclear Ribonucleoprotein C1/C2 Controls the Metastatic Potential of Glioblastoma by Regulating PDCD4. Mol. Cell. Biol. 2012, 32, 4237–4244. [Google Scholar] [CrossRef] [Green Version]
- Fang, X.; Yoon, J.-G.; Li, L.; Tsai, Y.S.; Zheng, S.; Hood, L.; Goodlett, D.R.; Foltz, G.; Lin, B. Landscape of the SOX2 protein-protein interactome. Proteomics 2011, 11, 921–934. [Google Scholar] [CrossRef]
- Li, Z.-W.; Xue, M.; Zhu, B.-X.; Yue, C.-L.; Chen, M.; Qin, H.-H. microRNA-4500 inhibits human glioma cell progression by targeting IGF2BP1. Biochem. Biophys. Res. Commun. 2019, 513, 800–806. [Google Scholar] [CrossRef]
- Luo, Y.; Sun, R.; Zhang, J.; Sun, T.; Liu, X.; Yang, B. miR-506 inhibits the proliferation and invasion by targeting IGF2BP1 in glioblastoma. Am. J. Transl. Res. 2015, 7, 2007–2014. [Google Scholar]
- Wang, R.-J.; Li, J.-W.; Bao, B.-H.; Wu, H.-C.; Du, Z.-H.; Su, J.-L.; Zhang, M.-H.; Liang, H.-Q. MicroRNA-873 (MiRNA-873) Inhibits Glioblastoma Tumorigenesis and Metastasis by Suppressing the Expression of IGF2BP1. J. Biol. Chem. 2015, 290, 8938–8948. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Li, X.; Zhou, Y.; Huang, X.; Jiang, X. Long non-coding RNA OIP5-AS1 inhibition upregulates microRNA-129-5p to repress resistance to temozolomide in glioblastoma cells via downregulating IGF2BP. Cell Biol. Toxicol. 2021, 38, 963–977. [Google Scholar] [CrossRef] [PubMed]
- Kouhkan, F.; Mobarra, N.; Soufi-Zomorrod, M.; Keramati, F.; Ali Hosseini Rad, S.M.; Fathi-Roudsari, M.; Tavakoli, R.; Hajarizadeh, A.; Ziaei, S.; Lahmi, R.; et al. MicroRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1. J. Med. Genet. 2015, 53, 24–33. [Google Scholar] [CrossRef] [Green Version]
- Mineo, M.; Ricklefs, F.; Rooj, A.K.; Lyons, S.M.; Ivanov, P.; Ansari, K.I.; Nakano, I.; Chiocca, E.A.; Godlewski, J.; Bronisz, A. The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Rep. 2016, 15, 2500–2509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Janiszewska, M.; Suvà, M.L.; Riggi, N.; Houtkooper, R.H.; Auwerx, J.; Clément-Schatlo, V.; Radovanovic, I.; Rheinbay, E.; Provero, P.; Stamenkovic, I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012, 26, 1926–1944. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, H.; Qin, S.; Liu, C.; Le Jiang, L.; Li, C.; Yang, J.; Zhang, S.; Yan, Z.; Liu, X.; Yang, J.; et al. m6A reader IGF2BP2-stabilized CASC9 accelerates glioblastoma aerobic glycolysis by enhancing HK2 mRNA stability. Cell Death Discov. 2021, 7, 292. [Google Scholar] [CrossRef] [PubMed]
- Han, J.; Yu, X.; Wang, S.; Wang, Y.; Liu, Q.; Xu, H.; Wang, X. IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR. Front. Cell Dev. Biol. 2022, 9, 659228. [Google Scholar] [CrossRef] [PubMed]
- Boriack-Sjodin, P.A.; Ribich, S.; Copeland, R.A. RNA-modifying proteins as anticancer drug targets. Nat. Rev. Drug Discov. 2018, 17, 435–453. [Google Scholar] [CrossRef]
- Cully, M. Chemical inhibitors make their RNA epigenetic mark. Nat. Rev. Drug Discov. 2019, 18, 892–894. [Google Scholar] [CrossRef] [PubMed]
- Qiao, Y.; Zhou, B.; Zhang, M.; Liu, W.; Han, Z.; Song, C.; Yu, W.; Yang, Q.; Wang, R.; Wang, S.; et al. A Novel Inhibitor of the Obesity-Related Protein FTO. Biochemistry 2016, 55, 1516–1522. [Google Scholar] [CrossRef]
- Chen, B.; Ye, F.; Yu, L.; Jia, G.; Huang, X.; Zhang, X.; Peng, S.; Chen, K.; Wang, M.; Gong, S.; et al. Development of Cell-Active N6-Methyladenosine RNA Demethylase FTO Inhibitor. J. Am. Chem. Soc. 2012, 134, 17963–17971. [Google Scholar] [CrossRef]
- Huff, S.; Kummetha, I.R.; Zhang, L.; Wang, L.; Bray, W.; Yin, J.; Kelley, V.; Wang, Y.; Rana, T.M. Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents. J. Med. Chem. 2022, 65, 10920–10937. [Google Scholar] [CrossRef]
- Huff, S.; Tiwari, S.K.; Gonzalez, G.M.; Wang, Y.; Rana, T.M. m6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells. ACS Chem. Biol. 2021, 16, 324–333. [Google Scholar] [CrossRef]
- Selberg, S.; Seli, N.; Kankuri, E.; Karelson, M. Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors. ACS Omega 2021, 6, 13310–13320. [Google Scholar] [CrossRef] [PubMed]
- Malacrida, A.; Rivara, M.; Di Domizio, A.; Cislaghi, G.; Miloso, M.; Zuliani, V.; Nicolini, G. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorganic Med. Chem. 2020, 28, 115300. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, H.; Hase, H.; Yoshida, T.; Tashiro, J.; Hirade, Y.; Kitae, K.; Tsujikawa, K. Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme. Chem. Biol. Drug Des. 2022, 100, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Selberg, S.; Blokhina, D.; Aatonen, M.; Koivisto, P.; Siltanen, A.; Mervaala, E.; Kankuri, E.; Karelson, M. Discovery of Small Molecules that Activate RNA Methylation through Cooperative Binding to the METTL3-14-WTAP Complex Active Site. Cell Rep. 2019, 26, 3762–3771.e5. [Google Scholar] [CrossRef] [Green Version]
- Bedi, R.K.; Huang, D.; Eberle, S.A.; Wiedmer, L.; Śledź, P.; Caflisch, A. Small-Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer. Chemmedchem 2020, 15, 744–748. [Google Scholar] [CrossRef]
- Li, J.; Gregory, R.I. Mining for METTL3 inhibitors to suppress cancer. Nat. Struct. Mol. Biol. 2021, 28, 460–462. [Google Scholar] [CrossRef]
- Moroz-Omori, E.V.; Huang, D.; Kumar Bedi, R.; Cheriyamkunnel, S.J.; Bochenkova, E.; Dolbois, A.; Rzeczkowski, M.D.; Li, Y.; Wiedmer, L.; Caflisch, A. METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes. Chemmedchem 2021, 16, 3035–3043. [Google Scholar] [CrossRef]
- Yankova, E.; Blackaby, W.; Albertella, M.; Rak, J.; De Braekeleer, E.; Tsagkogeorga, G.; Pilka, E.S.; Aspris, D.; Leggate, D.; Hendrick, A.G.; et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021, 593, 597–601. [Google Scholar] [CrossRef]
- Li, L.; Wu, M.; Wang, C.; Yu, Z.; Wang, H.; Qi, H.; Xu, X. β-Asarone Inhibits Invasion and EMT in Human Glioma U251 Cells by Suppressing Splicing Factor HnRNP A2/B1. Molecules 2018, 23, 671. [Google Scholar] [CrossRef] [Green Version]
- Liu, X.; Wu, P.; Su, R.; Xue, Y.; Yang, C.; Wang, D.; Ruan, X.; Zheng, J.; Yang, Y.; Li, Z.; et al. IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay. RNA Biol. 2020, 17, 1777–1788. [Google Scholar] [CrossRef]
- Shi, H.; Xu, Y.; Na Tian, N.; Yang, M.; Liang, F.-S. Inducible and reversible RNA N6-methyladenosine editing. Nat. Commun. 2022, 13, 1958. [Google Scholar] [CrossRef]
- Liu, X.-M.; Zhou, J.; Mao, Y.; Ji, Q.; Qian, S.-B. Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates. Nat. Chem. Biol. 2019, 15, 865–871. [Google Scholar] [CrossRef]
- Rau, K.; Roesner, L.; Rentmeister, A. Sequence-specific m6A demethylation in RNA by FTO fused to RCas9. RNA 2019, 25, 1311–1323. [Google Scholar] [CrossRef]
- Wilson, C.; Chen, P.J.; Miao, Z.; Liu, D.R. Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat. Biotechnol. 2020, 38, 1431–1440. [Google Scholar] [CrossRef]
- Xia, Z.; Tang, M.; Ma, J.; Zhang, H.; Gimple, R.C.; Prager, B.C.; Tang, H.; Sun, C.; Liu, F.; Lin, P.; et al. Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. Nucleic Acids Res. 2021, 49, 7361–7374. [Google Scholar] [CrossRef]
- Chang, C.; Ma, G.; Cheung, E.; Hutchins, A.P. A programmable system to methylate and demethylate N6-methyladenosine (m6A) on specific RNA transcripts in mammalian cells. J. Biol. Chem. 2022, 298, 102525. [Google Scholar] [CrossRef]
- Li, J.; Chen, Z.; Chen, F.; Xie, G.; Ling, Y.; Peng, Y.; Lin, Y.; Luo, N.; Chiang, C.-M.; Wang, H. Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. Nucleic Acids Res. 2020, 48, 5684–5694. [Google Scholar] [CrossRef]
- Sun, X.; Wang, D.O.; Wang, J. Targeted manipulation of m6A RNA modification through CRISPR-Cas-based strategies. Methods 2022, 203, 56–61. [Google Scholar] [CrossRef]
- Lo, N.; Xu, X.; Soares, F.; He, H.H. The Basis and Promise of Programmable RNA Editing and Modification. Front. Genet. 2022, 13, 834413. [Google Scholar] [CrossRef]
- Lan, L.; Sun, Y.; Jin, X.; Xie, L.; Liu, L.; Cheng, L. A Light-Controllable Chemical Modulation of m6A RNA Methylation. Angew. Chem. Int. Ed. 2021, 60, 18116–18121. [Google Scholar] [CrossRef] [PubMed]
- Bočkaj, I.; Martini, T.E.I.; De Camargo Magalhães, E.S.; Bakker, P.L.; Meeuwsen-De Boer, T.G.J.; Armandari, I.; Meuleman, S.L.; Mondria, M.T.; Stok, C.; Kok, Y.P.; et al. The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma. PLOS Genet. 2021, 17, e1009868. [Google Scholar] [CrossRef]
- Ferguson, L.R.; Chen, H.; Collins, A.R.; Connell, M.; Damia, G.; Dasgupta, S.; Malhotra, M.; Meeker, A.K.; Amedei, A.; Amin, A.; et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin. Cancer Biol. 2015, 35, S5–S24. [Google Scholar] [CrossRef]
- Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic instability—an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 220–228. [Google Scholar] [CrossRef] [PubMed]
- Alhmoud, J.F.; Woolley, J.F.; Al Moustafa, A.-E.; Malki, M.I. DNA Damage/Repair Management in Cancers. Cancers 2020, 12, 1050. [Google Scholar] [CrossRef] [Green Version]
- Ghosal, G.; Chen, J. DNA damage tolerance: A double-edged sword guarding the genome. Transl. Cancer Res. 2013, 2, 107–129. [Google Scholar] [CrossRef] [PubMed]
- Kalimutho, M.; Nones, K.; Srihari, S.; Duijf, P.H.; Waddell, N.; Khanna, K.K. Patterns of Genomic Instability in Breast Cancer. Trends Pharmacol. Sci. 2019, 40, 198–211. [Google Scholar] [CrossRef] [PubMed]
- Pikor, L.A.; Thu, K.; Vucic, E.; Lam, W. The detection and implication of genome instability in cancer. Cancer Metastasis Rev. 2013, 32, 341–352. [Google Scholar] [CrossRef] [Green Version]
- Bonora, M.; Missiroli, S.; Perrone, M.; Fiorica, F.; Pinton, P.; Giorgi, C. Mitochondrial Control of Genomic Instability in Cancer. Cancers 2021, 13, 1914. [Google Scholar] [CrossRef]
- Londoño-Vallejo, J.A. Telomere instability and cancer. Biochimie 2008, 90, 73–82. [Google Scholar] [CrossRef]
- Rinaldi, C.; Pizzul, P.; Longhese, M.P.; Bonetti, D. Sensing R-Loop-Associated DNA Damage to Safeguard Genome Stability. Front. Cell Dev. Biol. 2021, 8, 618157. [Google Scholar] [CrossRef]
- Wilhelm, T.; Said, M.; Naim, V. DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons. Genes 2020, 11, 642. [Google Scholar] [CrossRef] [PubMed]
- Crossley, M.P.; Bocek, M.; Cimprich, K.A. R-Loops as Cellular Regulators and Genomic Threats. Mol. Cell 2019, 73, 398–411. [Google Scholar] [CrossRef] [Green Version]
- Gan, W.; Guan, Z.; Liu, J.; Gui, T.; Shen, K.; Manley, J.L.; Li, X. R-loop-mediated genomic instability is caused by impairment of replication fork progression. Genes Dev. 2011, 25, 2041–2056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, X.; Liu, Q.-L.; Xu, W.; Zhang, Y.-C.; Yang, Y.; Ju, L.-F.; Chen, J.; Chen, Y.-S.; Li, K.; Ren, J.; et al. m6A promotes R-loop formation to facilitate transcription termination. Cell Res. 2019, 29, 1035–1038. [Google Scholar] [CrossRef] [PubMed]
- Gómez-González, B.; Aguilera, A. Looping the (R) Loop in DSB Repair via RNA Methylation. Mol. Cell 2020, 79, 361–362. [Google Scholar] [CrossRef] [PubMed]
- Chakraborty, P. New insight into the biology of R-loops. Mutat. Res. Mol. Mech. Mutagen. 2020, 821, 111711. [Google Scholar] [CrossRef]
- Patel, P.S.; Krishnan, R.; Hakem, R. Emerging roles of DNA topoisomerases in the regulation of R-loops. Mutat. Res. Toxicol. Environ. Mutagen. 2022, 876–877, 503450. [Google Scholar] [CrossRef]
- Kang, H.J.; Eom, H.-J.; Kim, H.; Myung, K.; Kwon, H.M.; Choi, J.H. Thrap3 promotes R-loop resolution via interaction with methylated DDX. Exp. Mol. Med. 2021, 53, 1602–1611. [Google Scholar] [CrossRef]
- Marnef, A.; Legube, G. m6A RNA modification as a new player in R-loop regulation. Nat. Genet. 2020, 52, 27–28. [Google Scholar] [CrossRef]
- Khan, E.S.; Danckwardt, S. Pathophysiological Role and Diagnostic Potential of R-Loops in Cancer and Beyond. Genes 2022, 13, 2181. [Google Scholar] [CrossRef] [PubMed]
- Marnef, A.; Legube, G. R-loops as Janus-faced modulators of DNA repair. Nat. Cell Biol. 2021, 23, 305–313. [Google Scholar] [CrossRef] [PubMed]
- Costantino, L.; Koshland, D. Genome-wide Map of R-Loop-Induced Damage Reveals How a Subset of R-Loops Contributes to Genomic Instability. Mol. Cell 2018, 71, 487–497.e3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jauregui-Lozano, J.; Escobedo, S.; Easton, A.; Lanman, N.A.; Weake, V.M.; Hall, H. Proper control of R-loop homeostasis is required for maintenance of gene expression and neuronal function during aging. Aging Cell 2022, 21, e13554. [Google Scholar] [CrossRef] [PubMed]
- Ui, A.; Chiba, N.; Yasui, A. Relationship among DNA double-strand break (DSB), DSB repair, and transcription prevents genome instability and cancer. Cancer Sci. 2020, 111, 1443–1451. [Google Scholar] [CrossRef]
- Hegazy, Y.A.; Fernando, C.M.; Tran, E.J. The balancing act of R-loop biology: The good, the bad, and the ugly. J. Biol. Chem. 2020, 295, 905–913. [Google Scholar] [CrossRef] [PubMed]
- Allison, D.F.; Wang, G.G. R-loops: Formation, function, and relevance to cell stress. Cell Stress 2019, 3, 38–46. [Google Scholar] [CrossRef] [Green Version]
- García-Muse, T.; Aguilera, A. R Loops: From Physiological to Pathological Roles. Cell 2019, 179, 604–618. [Google Scholar] [CrossRef]
- Abakir, A.; Giles, T.C.; Cristini, A.; Foster, J.M.; Dai, N.; Starczak, M.; Rubio-Roldan, A.; Li, M.; Eleftheriou, M.; Crutchley, J.; et al. N6-methyladenosine regulates the stability of RNA:DNA hybrids in human cells. Nat. Genet. 2020, 52, 48–55. [Google Scholar] [CrossRef]
- Kim, A.; Wang, G.G. R-loop and its functions at the regulatory interfaces between transcription and (epi)genome. Biochim. Et Biophys. Acta (BBA)—Gene Regul. Mech. 2021, 1864, 194750. [Google Scholar] [CrossRef]
- Mah, L.-J.; El-Osta, A.; Karagiannis, T.C. γH2AX: A sensitive molecular marker of DNA damage and repair. Leukemia 2010, 24, 679–686. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xi, Z.; Xue, Y.; Zheng, J.; Liu, X.; Ma, J.; Liu, Y. WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients. J. Mol. Neurosci. 2016, 60, 131–136. [Google Scholar] [CrossRef]
- Aparicio, T.; Baer, R.; Gautier, J. DNA double-strand break repair pathway choice and cancer. DNA Repair 2014, 19, 169–175. [Google Scholar] [CrossRef] [Green Version]
- Hoeijmakers, J.H.J. Molecular Origins of Cancer DNA Damage, Aging, and Cancer. N. Engl. J. Med. 2009, 361, 1475–1485. [Google Scholar] [CrossRef]
- Xiang, Y.; Laurent, B.; Hsu, C.-H.; Nachtergaele, S.; Lu, Z.; Sheng, W.; Xu, C.; Chen, H.; Ouyang, J.; Wang, S.; et al. RNA m6A methylation regulates the ultraviolet-induced DNA damage response. Nature 2017, 543, 573–576. [Google Scholar] [CrossRef] [Green Version]
- Zhang, C.; Chen, L.; Peng, D.; Jiang, A.; He, Y.; Zeng, Y.; Xie, C.; Zhou, H.; Luo, X.; Liu, H.; et al. METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. Mol. Cell 2020, 79, 425–442.e7. [Google Scholar] [CrossRef]
- Stirling, P.C.; Hieter, P. Canonical DNA Repair Pathways Influence R-Loop-Driven Genome Instability. J. Mol. Biol. 2017, 429, 3132–3138. [Google Scholar] [CrossRef] [PubMed]
- Widagdo, J.; Anggono, V.; Wong, J.J.-L. The multifaceted effects of YTHDC1-mediated nuclear m6A recognition. Trends Genet. 2022, 38, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Dong, Z.; Cui, H. The Emerging Roles of RNA Modifications in Glioblastoma. Cancers 2020, 12, 736. [Google Scholar] [CrossRef] [Green Version]
- Kang, H.J.; Cheon, N.Y.; Park, H.; Jeong, G.W.; Ye, B.J.; Yoo, E.J.; Lee, J.H.; Hur, J.-H.; Lee, E.-A.; Kim, H.; et al. TonEBP recognizes R-loops and initiates m6A RNA methylation for R-loop resolution. Nucleic Acids Res. 2021, 49, 269–284. [Google Scholar] [CrossRef]
- Ye, B.J.; Kang, H.J.; Lee-Kwon, W.; Kwon, H.M.; Choi, S.Y. PARP1-mediated PARylation of TonEBP prevents R-loop–associated DNA damage. DNA Repair 2021, 104, 103132. [Google Scholar] [CrossRef]
- Arora, R.; Lee, Y.; Wischnewski, H.; Brun, C.M.; Schwarz, T.; Azzalin, C.M. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nat. Commun. 2014, 5, 5220. [Google Scholar] [CrossRef] [Green Version]
- Stork, C.; Bocek, M.; Crossley, M.P.; Sollier, J.; Sanz, L.A.; Dé Ric Ché Din, F.; Swigut, T.; Cimprich, K.A. Co-Transcriptional R-Loops Are the Main Cause of Estrogen-Induced DNA Damage. eLife 2016, 5, e17548. [Google Scholar] [CrossRef]
- Zhang, X.; Chiang, H.-C.; Wang, Y.; Zhang, C.; Smith, S.; Zhao, X.; Nair, S.J.; Michalek, J.; Jatoi, I.; Lautner, M.; et al. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat. Commun. 2017, 8, 15908. [Google Scholar] [CrossRef] [Green Version]
- Prendergast, L.; McClurg, U.L.; Hristova, R.; Berlinguer-Palmini, R.; Greener, S.; Veitch, K.; Hernandez, I.; Pasero, P.; Rico, D.; Higgins, J.M.G.; et al. Resolution of R-loops by INO80 promotes DNA replication and maintains cancer cell proliferation and viability. Nat. Commun. 2020, 11, 4534. [Google Scholar] [CrossRef]
- Khan, R.I.N.; Malla, W.A. m6A modification of RNA and its role in cancer, with a special focus on lung cancer. Genomics 2021, 113, 2860–2869. [Google Scholar] [CrossRef]
- Li, X.; Ma, S.; Deng, Y.; Yi, P.; Yu, J. Targeting the RNA m6A modification for cancer immunotherapy. Mol. Cancer 2022, 21, 76. [Google Scholar] [CrossRef]
- Medikonda, R.; Dunn, G.; Rahman, M.; Fecci, P.; Lim, M. A review of glioblastoma immunotherapy. J. Neuro-Oncol. 2021, 151, 41–53. [Google Scholar] [CrossRef]
- Pan, J.; Huang, T.; Deng, Z.; Zou, C. Roles and therapeutic implications of m6A modification in cancer immunotherapy. Front. Immunol. 2023, 14, 1132601. [Google Scholar] [CrossRef]
- Zhang, R.; Li, S.-W.; Liu, L.; Yang, J.; Huang, G.; Sang, Y. TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis 2020, 9, 45. [Google Scholar] [CrossRef]
- Li, N.; Kang, Y.; Wang, L.; Huff, S.; Tang, R.; Hui, H.; Agrawal, K.; Michelle Gonzalez, G.; Wang, Y.; Patel, S.P.; et al. ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc. Natl. Acad. Sci. USA 2020, 117, 20159–20170. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Hui, H.; Agrawal, K.; Kang, Y.; Li, N.; Tang, R.; Yuan, J.; Rana, T.M. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020, 39, e104514. [Google Scholar] [CrossRef] [PubMed]
- Bao, Y.; Zhai, J.; Chen, H.; Wong, C.C.; Liang, C.; Ding, Y.; Huang, D.; Gou, H.; Chen, D.; Pan, Y.; et al. Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut 2023. Online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Ying, X.; Huang, Y.; Liu, B.; Hu, W.; Ji, D.; Chen, C.; Zhang, H.; Liang, Y.; Lv, Y.; Ji, W. Targeted m6A demethylation of ITGA6 mRNA by a multisite dCasRx–m6A editor inhibits bladder cancer development. J. Adv. Res. 2023. Online ahead of print. [Google Scholar] [CrossRef]
- Hu, L.; Liu, S.; Peng, Y.; Ge, R.; Su, R.; Senevirathne, C.; Harada, B.T.; Dai, Q.; Wei, J.; Zhang, L.; et al. m6A RNA modifications are measured at single-base resolution across the mammalian transcriptome. Nat. Biotechnol. 2022, 40, 1210–1219. [Google Scholar] [CrossRef]
- Mani, D.R.; Krug, K.; Zhang, B.; Satpathy, S.; Clauser, K.R.; Ding, L.; Ellis, M.; Gillette, M.A.; Carr, S.A. Cancer proteogenomics: Current impact and future prospects. Nat. Rev. Cancer 2022, 22, 298–313. [Google Scholar] [CrossRef]
- Rodriguez, H.; Zenklusen, J.C.; Staudt, L.M.; Doroshow, J.H.; Lowy, D.R. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell 2021, 184, 1661–1670. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Deacon, S.; Walker, L.; Radhi, M.; Smith, S. The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches. Cancers 2023, 15, 3307. https://doi.org/10.3390/cancers15133307
Deacon S, Walker L, Radhi M, Smith S. The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches. Cancers. 2023; 15(13):3307. https://doi.org/10.3390/cancers15133307
Chicago/Turabian StyleDeacon, Simon, Lauryn Walker, Masar Radhi, and Stuart Smith. 2023. "The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches" Cancers 15, no. 13: 3307. https://doi.org/10.3390/cancers15133307
APA StyleDeacon, S., Walker, L., Radhi, M., & Smith, S. (2023). The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches. Cancers, 15(13), 3307. https://doi.org/10.3390/cancers15133307